Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100OYAV
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥643.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.7bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥4.6bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.33Tat 2022-06-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.34Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥852.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥486.2bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥178.2bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.322021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30¥126m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥567.7bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥563.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥4.2bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥534m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥272m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥63.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥63.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥113m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥444m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥650.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥643.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥3.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Valuation and translation adjustmentsCurrentQuarterInstant51050000000JPY
Non controlling interestsPrior1YearInstant241000000JPY
Non controlling interestsCurrentQuarterInstant276000000JPY
Net assetsPrior1YearInstant471835000000JPY
Net assetsCurrentQuarterInstant475488000000JPY
Liabilities and net assetsPrior1YearInstant1303991000000JPY
Liabilities and net assetsCurrentQuarterInstant1328026000000JPY
Net salesPrior1YTDDuration643586000000JPY
Net salesCurrentYTDDuration657122000000JPY
Cost of salesPrior1YTDDuration600222000000JPY
Cost of salesCurrentYTDDuration614629000000JPY
Gross profitPrior1YTDDuration43363000000JPY
Gross profitCurrentYTDDuration42493000000JPY
Selling general and administrative expensesPrior1YTDDuration39517000000JPY
Selling general and administrative expensesCurrentYTDDuration39404000000JPY
Operating incomePrior1YTDDuration3846000000JPY
Operating incomeCurrentYTDDuration3088000000JPY
Interest income noiPrior1YTDDuration11000000JPY
Interest income noiCurrentYTDDuration10000000JPY
Dividends income noiPrior1YTDDuration545000000JPY
Dividends income noiCurrentYTDDuration362000000JPY
Real estate rent noiPrior1YTDDuration154000000JPY
Real estate rent noiCurrentYTDDuration155000000JPY
Other noiPrior1YTDDuration288000000JPY
Other noiCurrentYTDDuration184000000JPY
Non operating incomePrior1YTDDuration999000000JPY
Non operating incomeCurrentYTDDuration713000000JPY
Interest expenses noePrior1YTDDuration20000000JPY
Interest expenses noeCurrentYTDDuration17000000JPY
Rent expenses on real estates noePrior1YTDDuration47000000JPY
Rent expenses on real estates noeCurrentYTDDuration47000000JPY
Other noePrior1YTDDuration48000000JPY
Other noeCurrentYTDDuration30000000JPY
Non operating expensesPrior1YTDDuration115000000JPY
Non operating expensesCurrentYTDDuration95000000JPY
Ordinary incomePrior1YTDDuration4730000000JPY
Ordinary incomeCurrentYTDDuration3706000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on sales of investment securities eiPrior1YTDDuration3000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration5000000JPY
Extraordinary incomeCurrentYTDDuration0JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration2000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration74000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration22000000JPY
Impairment loss elPrior1YTDDuration2000000JPY
Impairment loss elCurrentYTDDuration1000000JPY
Loss on valuation of investment securities elPrior1YTDDuration56000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass